Courtney Crane, PhD

Courtney Crane, PhD

Children's Title: Principal Investigator, Ben Towne Center for Childhood Cancer Research

Academic Title: Associate Professor

Research Center: Ben Towne Center for Childhood Cancer Research

"Children with brain tumors are limited to treatments like surgery, chemotherapy and radiation that can have lifelong side effects. My research focuses on developing safer and more effective treatments using cellular immunotherapy techniques that could wipe out the cancer and eliminate the potential devastating impact of todays treatments. I am optimistic that immunotherapy will bring the possibility of a one-time curative treatment for solid tumor cancer within our reach."

  • Dr. Courtney Crane is a principal investigator at the Ben Towne Center and an assistant professor at the University of Washington School of Medicine. Her lab is unraveling how cancer cells disarm immune cells, with the goal of finding ways to reprogram those immune cells so they can elude cancer's defenses.

    Crane received her PhD from the University of Virginia and completed a research fellowship in the department of neurosurgery at the University of California, San Francisco.

    • Related Resources

  • Other Publications

    • Lieberman NAP, DeGolier K, Kovar HM, Davis A, Hoglund V, Stevens J, Winter C, Deutsch G, Furlan SN, Vitanza NA, Leary SES, Crane CA
      Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy.
      30169876 Neuro-oncology, 2019 Jan. 1 : 21(1)83-94 PMCID:PMC6303470
    • Lieberman NAP, Vitanza NA, Crane CA
      Immunotherapy for brain tumors: understanding early successes and limitations.
      29322843 Expert review of neurotherapeutics, 2018 March : 18(3)251-259
    • Lieberman NAP, DeGolier K, Haberthur K, Chinn H, Moyes KW, Bouchlaka MN, Walker KL, Capitini CM, Crane CA
      An Uncoupling of Canonical Phenotypic Markers and Functional Potency of Ex Vivo-Expanded Natural Killer Cells.
      29456538 Frontiers in immunology, 2018 : 9150 PMCID:PMC5801405
    • Moyes KW, Davis A, Hoglund V, Haberthur K, Lieberman NA, Kreuser SA, Deutsch GH, Franco S, Locke D, Carleton MO, Gilbertson DG, Simmons R, Winter C, Silber J, Gonzalez-Cuyar LF, Ellenbogen RG, Crane CA
      Effects of tumor grade and dexamethasone on myeloid cells in patients with glioma.
      30377570 Oncoimmunology, 2018 : 7(11)e1507668 PMCID:PMC6204983
    • Moyes KW, Lieberman NA, Kreuser SA, Chinn H, Winter C, Deutsch G, Hoglund V, Watson R, Crane CA
      Genetically Engineered Macrophages: A Potential Platform for Cancer Immunotherapy.
      27758144 Human gene therapy, 2017 Feb. : 28(2)200-215
    • Haberthur K, Brennan K, Hoglund V, Balcaitis S, Chinn H, Davis A, Kreuser S, Winter C, Leary SE, Deutsch GH, Ellenbogen RG, Crane CA
      NKG2D ligand expression in pediatric brain tumors.
      27834580 Cancer biology & therapy, 2016 Dec. : 17(12)1253-1265 PMCID:PMC5199167
    • Lieberman NA, Moyes KW, Crane CA
      Developing immunotherapeutic strategies to target brain tumors.
      27253692 Expert review of anticancer therapy, 2016 July : 16(7)775-88
    • Crane CA, Austgen K, Haberthur K, Hofmann C, Moyes KW, Avanesyan L, Fong L, Campbell MJ, Cooper S, Oakes SA, Parsa AT, Lanier LL
      Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients.
      25136121 Proceedings of the National Academy of Sciences of the United States of America, 2014 Sept. 2 : 111(35)12823-8 PMCID:PMC4156766
    • Bloch O, Crane CA, Fuks Y, Kaur R, Aghi MK, Berger MS, Butowski NA, Chang SM, Clarke JL, McDermott MW, Prados MD, Sloan AE, Bruce JN, Parsa AT
      Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial.
      24335700 Neuro-oncology, 2014 Jan. : 16(2)274-9 PMCID:PMC3895386
    • Bloch O, Crane CA, Kaur R, Safaee M, Rutkowski MJ, Parsa AT
      Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages.
      23613317 Clinical cancer research : an official journal of the American Association for Cancer Research, 2013 June 15 : 19(12)3165-75 PMCID:PMC3742575
    • Crane CA, Han SJ, Ahn B, Oehlke J, Kivett V, Fedoroff A, Butowski N, Chang SM, Clarke J, Berger MS, McDermott MW, Prados MD, Parsa AT
      Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein.
      22872572 Clinical cancer research : an official journal of the American Association for Cancer Research, 2013 Jan. 1 : 19(1)205-14
    • Crane CA, Ahn BJ, Han SJ, Parsa AT
      Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy.
      22406925 Neuro-oncology, 2012 May : 14(5)584-95 PMCID:PMC3337302
    • Panner A, Crane CA, Weng C, Feletti A, Fang S, Parsa AT, Pieper RO
      Ubiquitin-specific protease 8 links the PTEN-Akt-AIP4 pathway to the control of FLIPS stability and TRAIL sensitivity in glioblastoma multiforme.
      20484045 Cancer research, 2010 June 15 : 70(12)5046-53 PMCID:PMC2891229

Overview

Medical/Professional School

University of Virginia, Charlottesville

Fellowship

University of California, San Francisco, San Francisco

Research Description

Dr. Crane's major area of interest is in the identification of novel targets for cellular immunotherapies for patients with malignant brain tumors.

About My Work

https://www.seattlechildrens.org/research/centers-programs/childhood-cancer/our-science/our-labs/crane-lab/

Research Focus Area

Cancer